Navigation Links
NeurogesX Completes Enrollment in Confirmatory Phase 3 Clinical Trial for Painful HIV Distal Sensory Polyneuropathy
Date:9/21/2007

ited to, past results of clinical trials may not be indicative of future clinical trials results; NeurogesX' product candidate may have unexpected adverse side effects or inadequate therapeutic efficacy; positive results in clinical trials may not be sufficient to obtain FDA or European regulatory approval; physician or patient reluctance to use NGX-4010, if approved, or the inability of physicians to obtain sufficient reimbursement for such procedures; potential alternative therapies; maintaining adequate patent or trade secret protection without violating the intellectual property rights of others; and other difficulties or delays in clinical development, obtaining regulatory approval, market acceptance and commercialization of NGX-4010 and the advantages of NGX-4010 over other pain therapies. For further information regarding these and other risks related to NeurogesX' business, investors should consult NeurogesX' filings with the Securities and Exchange Commission.


'/>"/>
SOURCE NeurogesX, Inc.
Copyright©2007 PR Newswire.
All rights reserved

Page: 1 2 3 4

Related medicine technology :

1. NeurogesX Announces Presentation of Positive Phase 3 Clinical Data at the Second International Congress on Neuropathic Pain Meeting (NeuPSIG)
2. Lev Pharmaceuticals Completes Phase III Prophylaxis Trial of C1-Esterase Inhibitor for Hereditary Angioedema
3. Celsion Completes Enrollment in Phase I Liver Cancer Study
4. LANI completes Phase I in Japan and to commence Phase I in UK
5. Ace Biosciences, Ace393, the Worlds First Commercial Vaccine for Travellers Diarrhoea Caused by Campylobacter Successfully Completes Phase I Clinical Trials
6. AVI BioPharma Partner Cook Medical Announces Completion of Patient Enrollment for APPRAISAL Phase II Clinical Trial for Treatment of Cardiovascular Disease
7. NexMed Announces Completion of Patient Enrollment in Two Pivotal Phase 3 Studies for Anti-Fungal Product
8. MediQuest Concludes Confirmatory Phase III Study of Raynaud’s Therapy
9. Data Available From Erbitux Phase III Study in First-Line Treatment of Advanced Lung Cancer
10. Phase 3 Results for Dabigatran Etexilate, an Investigational Oral Anticoagulant, Presented Today at the XXIst Congress of the International Society on Thrombosis and Haemostasis
11. YM BioSciences Announces Secondary Efficacy and Safety Findings in Randomized Phase IIB Aerolef Trial
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:7/11/2014)... LONDON , July 11, 2014 ... ended at 4,396.20, down 0.52%, the Dow Jones Industrial Average ... 500 closed at 1,964.68, down 0.41%. The losses were broad ... in negative. The S&P 500 Health Care Sector Index ended ... advanced 2.75% in the last one month. Investor-Edge has initiated ...
(Date:7/11/2014)... 11, 2014 Show ... & Health Expo 2014 were a brand ... London , plus a ...          (Logo: http://photos.prnewswire.com/prnh/20130723/629764-a) ... )      (Photo: http://photos.prnewswire.com/prnh/20140711/696892-b ...
(Date:7/10/2014)... CLEVELAND , July 10, 2014  The U.S. ... a three-year grant to University Hospitals (UH) Case Medical ... a new national model aimed at improving care for ... Oncology Care," the project will test a unique model ... patients with late-stage disease, significant comorbidities, or demonstrated need ...
Breaking Medicine Technology:Health Care Equipment Equities Movers and Shakers -- Research on Covidien, Baxter, DexCom, and Boston Scientific 2Health Care Equipment Equities Movers and Shakers -- Research on Covidien, Baxter, DexCom, and Boston Scientific 3Health Care Equipment Equities Movers and Shakers -- Research on Covidien, Baxter, DexCom, and Boston Scientific 4UK's Flagship Health & Safety Event Has Successful Inaugural Year in London 2UK's Flagship Health & Safety Event Has Successful Inaugural Year in London 3UK's Flagship Health & Safety Event Has Successful Inaugural Year in London 4University Hospitals Case Medical Center Awarded $4.7 Million Grant from U.S. Department of Health and Human Services 2University Hospitals Case Medical Center Awarded $4.7 Million Grant from U.S. Department of Health and Human Services 3University Hospitals Case Medical Center Awarded $4.7 Million Grant from U.S. Department of Health and Human Services 4
... indicate early non-responders unlikely to subsequently,respond, have ... earlier change in treatment strategy, COLORADO SPRINGS, ... presented at the 2007 International Congress on,Schizophrenia ... assessed earlier than is presently thought, and,challenge ...
... Time Reduced By an Average of More ... PARK, N.C., April 02, 2007 /PRNewswire/ --,Adding ... XL 24-Hour(TM) Extended-Release Tablets to,Parkinson's patients' existing ... patients to continue,their daily activities for a ...
Cached Medicine Technology:New Data Show Early Non-Response to Antipsychotic Treatment May Be,Strong Predictor of Subsequent Non-Response for People with,Schizophrenia 2New Data Show Early Non-Response to Antipsychotic Treatment May Be,Strong Predictor of Subsequent Non-Response for People with,Schizophrenia 3New Data Show Early Non-Response to Antipsychotic Treatment May Be,Strong Predictor of Subsequent Non-Response for People with,Schizophrenia 4New Data Show Early Non-Response to Antipsychotic Treatment May Be,Strong Predictor of Subsequent Non-Response for People with,Schizophrenia 5New Data Show Early Non-Response to Antipsychotic Treatment May Be,Strong Predictor of Subsequent Non-Response for People with,Schizophrenia 6Once Daily, Extended-Release Ropinirole Improves Parkinson's,Symptoms in Patients not Optimally Controlled With Levodopa 2Once Daily, Extended-Release Ropinirole Improves Parkinson's,Symptoms in Patients not Optimally Controlled With Levodopa 3Once Daily, Extended-Release Ropinirole Improves Parkinson's,Symptoms in Patients not Optimally Controlled With Levodopa 4Once Daily, Extended-Release Ropinirole Improves Parkinson's,Symptoms in Patients not Optimally Controlled With Levodopa 5
(Date:7/11/2014)... July 11, 2014 Fadhits.com, the distinguished ... elegant assortment of lace holiday dresses . To ... are now offered at discounted prices, up to 65% ... can enjoy this special offer. , Fadhits.com is ... special occasion dresses for the global clients. All its ...
(Date:7/11/2014)... New research from UC San Francisco shows that ... Medea Project helps women living with HIV disclose ... self-efficacy and the safety and quality of their ... study,s first author, Edward L. Machtinger, MD, director ... 90 percent of our patients are on effective ...
(Date:7/11/2014)... CA (PRWEB) July 11, 2014 Bedros Keuilian ... expert; a title he’s earned by founding the fast-selling fitness ... on marketing their businesses. He works with successful boot camp ... blog post on the traits of the most successful boot ... share three important qualities. , “I’ve worked with and coached ...
(Date:7/11/2014)... When the mercury rises, heat can strain the limits of ... on a heavier load in hot weather to keep body ... Harvard Men's Health Watch . , For otherwise fit, ... their limits and drinking enough fluids. But what about men ... to the heat," says Dr. Joanne Foody, Director of cardiovascular ...
(Date:7/11/2014)... As reported by Forbes in the article Robert ... Blame (6/30), Indino Downey has reportedly been arrested after ... it with. His father, well-known actor Robert Downey Jr. ... him may have something to do with his addiction ... 1980s and 1990s for substance abuse before finally getting ...
Breaking Medicine News(10 mins):Health News:Elegant Lace Holiday Dresses Released by Fadhits.com 2Health News:'Expressive therapy" intervention assists women living with HIV 2Health News:Fitness Boot Camp Marketing Expert Bedros Keuilian Shares the Top Three Traits of Successful Boot Camp Owners 2Health News:Fitness Boot Camp Marketing Expert Bedros Keuilian Shares the Top Three Traits of Successful Boot Camp Owners 3Health News:Take Common Sense Steps to Stay Safe This Summer, from the July 2014 Harvard Men's Health Watch 2Health News:Take Common Sense Steps to Stay Safe This Summer, from the July 2014 Harvard Men's Health Watch 3Health News:Roberty Downey's Son Arrested For Cocaine 2
... ON, Dec. 28 /PRNewswire-FirstCall/ - AlphaRx Inc. (OTC ... Nanotechnology for Drug Delivery,Platforms, announce that in order ... CFO, directors, consultants and employees plan to,exercise stock ... Michael Lee, President and CEO, will cancel 6,000,000 ...
... Utah, Dec. 28 A Utah company wants to ... Trainer Pro.,MediaRif,s online software takes the complexity out of ... training is on the rise, and not just for ... that 21.9% of women use,strength training as a part ...
... Scientific,Corporation (NYSE: BSX ) today announced CE ... (CRT-D), which treats heart,failure and helps protect patients ... is specifically designed to monitor heartbeats in heart,failure ... improve the,heart,s pumping ability., The LIVIAN CRT-D, ...
... Company,(MSC), a leader in providing medical products and ... Bode as Senior Vice President,Ancillary Sales. Bode will ... MSC,s ancillary sector., (Logo: http://www.newscom.com/cgi-bin/prnh/20050912/FLM025LOGO ... the workers, compensation industry.,He previously served as Vice ...
... Caraco Pharmaceutical,Laboratories, Ltd., (Amex: CPD ) announced today ... final approval for the Company,s,Abbreviated New Drug Application (ANDA) ... and 10 mg, (Cetirizine HCl)., Cetirizine HCl, which ... strengths of 5 mg and 10 mg, is an ...
... The Facility, an Extension of the Philadelphia Ronald ... with an Inaugural House-Lighting Ceremony on, ... Monday, January 7th, PHILADELPHIA, Dec. 28 ... and Erie" will,officially open its doors on Monday, ...
Cached Medicine News:Health News:AlphaRx Officers and Directors To Exercise Options, Warrants and Retain Shares 2Health News:Personal Fitness Training Goes Online for 2008 2Health News:Boston Scientific Announces CE Mark Approval for Next-Generation Cardiac Resynchronization Therapy Defibrillator 2Health News:Boston Scientific Announces CE Mark Approval for Next-Generation Cardiac Resynchronization Therapy Defibrillator 3Health News:Caraco Pharmaceutical Laboratories, Ltd. Announces FDA Approval to Market Generic OTC Versions of Zyrtec Allergy Tablets(R) and Zyrtec Hives Relief Tablets(R) 2Health News:'Philadelphia Ronald McDonald House(R) at Front & Erie' Celebrates Grand Opening 2
Integra Epilepsy grid electrodes are thin and flexible for easier placement and to conform to the curvature of the cortical surface. Lead tunneling is done using a 14-gauge tunneling needle (ET-2)....
... design of Ad-Techs Spencer Probe Depth Electrodes ... introduced the one-piece main body structure which ... formulae that actually become more flexible as ... of depth electrodes feature a small 1.0 ...
Acufex arthroscopic electrodes are insulated for use in all fluids and come in boxes of 10....
... This implant essentially has the same ... concavities being more pronounced to provide for ... suture holes designed for use in suture ... provide temporary postoperative stability while a capsuloligamentous ...
Medicine Products: